Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Cancer Immunol Res. 2019 Jan 11;7(3):458–465. doi: 10.1158/2326-6066.CIR-18-0226

Fig 4.

Fig 4.

Increased on-treatment TIL clonality and T-cell fraction in tumor samples correlate with clinical benefit (P = 0.002, OR = 30). Changes in TIL clonality and T-cell fraction were determined by subtracting values determined at baseline from those determined in week 13 biopsies. P value was obtained from a Fisher’s exact test of CR/PR versus SD/PD comparing the top right quadrant to the remaining three quadrants.